Skip to main content
. 2021 Jan 28;16(1):e0243964. doi: 10.1371/journal.pone.0243964

Table 2. Administered treatments and therapeutic needs.

Total (n = 318) Survivors (n = 271) Non-survivors (n = 47) P value
Need for oxygen supplementation 259 (81.4%) 215 (79.3%) 44 (93.6%) 0.024
Needed high oxygen volume 74 (23.9%) 38 (14.4%) 36 (78.3%) <0.001
Mechanical Assisted Ventilation (non-invasive)
 CPAP 3 (0.943%) 2 (0.743%) 1 (2.22%) 0.372
 High flux Oxygen 27 (8.49%) 18 (6.69%) 9 (20%) 0.007
Entered Intensive Care 37 (11.8%) 24 (8.96%) 13 (28.3%) 0.001
Mechanical Assisted Ventilation (invasive) 25 (7.91%) 12 (4.44%) 13 (28.3%) <0.001
Hydroxychloroquine 297 (93.4%) 257 (94.8%) 40 (85.1%) 0.022
Azithromycin 281 (88.6%) 244 (90.4%) 37 (78.7%) 0.042
Lopinavir/Ritonavir 209 (65.7%) 180 (66.4%) 29 (61.7%) 0.618
Interferon 37 (11.7%) 27 (10%) 10 (21.3%) 0.045
High Dose Corticosteroids PT 64 (20.1%) 60 (22.1%) 4 (8.51%) 0.031
Low Dose Corticosteroids 68 (21.4%) 57 (21%) 11 (23.4%) 0.702
Tozilizumab 24 (7.59%) 17 (6.32%) 7 (14.9%) 0.066
Immunoglobulins 3 (0.943%) 3 (1.11%) 0 (0%) 1
Anakinra 2 (0.629%) 2 (0.738%) 0 (0%) 1
Vitamin D Supplementation 37 (11.6%) 36 (13.3%) 1 (2.13%) 0.025
Anticoagulants: prophylactic dose 233 (73.3%) 200 (74.6%) 33 (70.2%) 0.589
Anticoagulants: intermediate dose 24 (7.55%) 22 (8.18%) 2 (4.26%) 0.551
Anticoagulants: full dose
 DOACs 5 (1.57%) 5 (1.86%) 0 (0%) 1
 LMWH 83 (26.1%) 61 (22.7%) 22 (46.8%) 0.001

CPAP, continuous positive airway pressure. High Dose Corticosteroids PT, high dose corticosteroids pulse therapy. DOACs, direct-acting oral anticoagulants. LMWH, low-molecular-weight-heparin. Numerical variables are presented as mean (standard deviation). Categorical variables are presented as total number with percentages. P values were computed with a Student t-test (numerical variables) or Fisher’s exact test (categorical variables).